Telehealth Services

“Telehealth Service” is defined as a medical practitioner delivered health service provided to a patient via live image transmission of those images to a receiving medical practitioner at another approved site, through the use of video technology. "Video technology" means the recording, reproducing and broadcasting of live visual images utilizing a direct interactive video link with a patient. If the sending and/or receiving medical practitioner are not in a Health Authority approved site, the medical practitioner is responsible for the confidentiality and security of all records and transmissions related to the telehealth service. In order for payment to be made, the patient must be in attendance at the sending site at the time of the video capture. Only those services which are designated as telehealth services are payable by MSP. Other services/procedures require face-to-face encounters. Telehealth services do not include teleradiology or tele-ultrasound, which are regulated by their specific Sectional Preambles.

Telehealth services are payable only when provided as defined under the specific Preamble pertaining to the service rendered (e.g.: telehealth consultation - see Preamble D. 2.) to a patient with valid medical coverage. Patients must be informed and given opportunity to agree to services rendered using this modality, without prejudice.

Notwithstanding the above, "telehealth examination" means an examination of a patient by the consultant at the receiving site using "telehealth services" as defined above, but does not include the "face-to-face encounter" requirements referred to under Preamble A. 2. 

In those cases where a specialist service requires a general practitioner at the patient’s site to assist with the essential physical assessment, without which the specialist service would be ineffective, the specialist must indicate in the "Referred by" field that a request was made for a General Practice assisted assessment. 

Where a receiving medical practitioner, after having provided a telehealth consultation service to a patient, decides s/he must examine the patient in person, the medical practitioner should claim the subsequent visit as a limited consultation, unless more than 6 months has passed since the telehealth consultation. 

Where a telehealth service is interrupted for technical failure, and is not able to be resumed within a reasonable period of time, and therefore is unable to be completed, the receiving medical practitioner should submit a claim under the appropriate miscellaneous code for independent consideration with appropriate substantiating information.

Video technology services are generally payable once per patient/per day/per medical practitioner. Any exceptions to this policy must comply with all Payment Schedule criteria for multiple visits. Information regarding the medical necessity and times of service should accompany claims. 

Compensation for travel, scheduling and other logistics is the responsibility of the Regional Health Authority. Rural Retention fee-for-service premiums are applicable to telehealth services and are payable based on the location of the receiving medical practitioner in eligible RSA communities. 

The College of Physicians and Surgeons of British Columbia have confirmed that in this province, licensure is defined by the location of the medical practitioner. However, other jurisdictions may have other definitions. BC medical practitioners providing care via telehealth to patients outside the province must abide by the regulations set in the patient’s home province.

Services Not Listed in the Schedule

On recommendation of the BCMA Tariff Committee and agreed to by Government, interim listings may be designated by the MSC for new procedures or other services for a limited period of time to allow definitive listings to be established.

Miscellaneous Services

This section relates to services not listed in the MSC Payment Schedule that are:

• new medically necessary services generally considered to be accepted standards of care in the medical community currently and not considered experimental in nature; 

• unusually complex procedures, for established but infrequently performed procedures; 

• for unlisted “team” procedures, or 

• for any medically required service for which the medical practitioner desires independent consideration to be given by MSP

Claims under a miscellaneous fee code will be accepted for adjudication only if the following criteria are fulfilled:

• An estimate of an appropriate fee, with rationale for the level of that fee 

• Sufficient documentation of the services (such as the operative report) to substantiate the claim.  

The Medical Services Plan will review the fee estimate proposed and the supporting documentation and by comparing with the service provided with comparable services listed in the MSC Payment Schedule, determine the level of compensation. While an application for a new fee item is in process (as per Section C. 2.), MSP will pay for the service at a percentage of a comparable fee until the new fee item is effective. Should it be determined that a new listing will not be established due to the infrequency of the unlisted service, payments will be made at 100% of the comparable service.

ADMINISTRATIVE ITEMS

Fees Payable by the Medical Services Plan (MSP)

A Payment Schedule for medical practitioners is established under Section 26 of the Medicare Protection Act and is referred to in the Master Agreement between the Government of the Province of British Columbia and the Medical Services Commission (MSC) and the British Columbia Medical Association (BCMA). The fees listed are the amounts payable by the Medical Services Plan (MSP) of British Columbia for listed benefits. “Benefits” under the Act are limited to services which are medically required for the diagnosis and/or treatment of a patient, which are not excluded by legislation or regulation, and which are rendered personally by medical practitioners or by others delegated to perform them in accordance with the Commission’s policies on delegated services.

Services requested or required by a “third party” for other than medical requirements are not insured under MSP. Services such as consultations, laboratory investigations, anesthesiology, surgical assistance, etc., rendered solely in association with other services which are not benefits also are not considered benefits under MSP, except in special circumstances as approved by the Medical Services Commission

Setting and Modification of Fees 

The tri-partite Medical Services Commission (MSC) manages the Medical Services Plan (MSP) on behalf of the Government of British Columbia in accordance with the Medicare Protection Act and Regulations. The MSC is the body that has the statutory authority to set the fees that are payable for insured medical services provided to beneficiaries enrolled with the Medical Services Plan (MSP). The MSC Payment Schedule is the official list of fees for which insured services are paid by MSP.

The BC Medical Association (BCMA) maintains and publishes the BCMA Guide to Fees. The Guide mirrors the MSC Payment Schedule, with some exceptions including recommended private fees for uninsured services.

The practice of allergology

The allergist is especially competent in appropriately providing the following treatments:

• Antihistamines 

• Mast cell stabilizers

 • Bronchodilators

• Nasal, oral, ocular, topical, and inhaled glucocorticosteroids 

• Decongestants 

• Leukotriene modifiers 

• Phosphodiesterase modifiers, including theophylline 

• Adrenergic agonists 

• Anticholinergics (oral, topical and inhaled) 

• Mucolytics 

• Antibiotics 

• Adrenaline, epinephrine 

• All other pharmacologic and immunologic agents used to treat allergic and immunologic diseases The allergist is uniquely aware of the pharmacologic properties of the treatments, their limitations and side effects. He/she is also keenly aware of how other medications may affect allergic processes and cause allergic conditions, for example, coughing and angioedema (ACE inhibitors).

Allergists treat a variety of skin conditions and are expert in the use of: 

• Emollients 

• Antibiotics 

• Topical glucocorticosteroids 

• Immune modulators and all other agents and techniques used to manage eczema and other allergic skin disorders

Part of the current therapeutic arsenal includes: 

• Use of immune modulators, such as specific allergen immunotherapy (oral and injective) 

• Immunoglobulin replacement used to treat allergic and immunologic disorders 

• Monoclonal antibodies, including anti-IgE

Part of the education of patients involves: 

• Instruction on the methods and value of allergen avoidance techniques 

• Avoidance diets and nutritional implications of dietary modification 

In particular for pediatric patients the allergist should be able to educate the parents, relatives and teachers about ways to optimize the prevention and treatment of allergies in children. 

In order to apply all these treatments properly, the allergist must have current and ongoing knowledge of national and international guidelines for the management of allergic and immunologic disorders in adults and children, with particular emphasis on safety and efficacy of all therapies. 

The membership of WAO is approximately 35,000 allergists worldwide representing the bulk of the trained allergists globally. In some developed countries such as Japan, Germany and the US, there are 4,000-8,000 trained allergists per country, representing about 1 allergist per 25,000 to 75,000 patients. It is estimated that ideal care would be provided by about 1 allergist per 20,000-50,000 patients, provided that the medical community was trained and competent to provide first and second level care by primary care physicians and other organrelated specialists. On the other hand, there are countries such as Costa Rica with less than 10 allergists and others with even fewer. Thus, the huge number, diversity and importance of patients with allergic diseases is overwhelmed by the inadequacy of the training of the medical community to provide care to these sick and needy patients. It is in part from this pressing need that this White Book on allergy was developed.

The practice of allergology

The practice of allergy involves the diagnosis and care of patients with:

• Rhino-conjunctivitis, along with nonallergic rhinopathy

• Sinusitis, both acute and chronic, alone or complicated with nasal polyps 

• Otitis and Eustachian tube disorders 

• Asthma and all its forms including cough-variant asthma and exercise-induced asthma 

• Cough from all causes 

• Bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema 

• Hypersensitivity pneumonitis 

• Alveolitis 

• Atopic dermatitis/eczema 

• Contact dermatitis 

• Urticaria and angioedema 

• Drug allergy 

• Food allergy 

• Latex allergy 

• Insect allergy and stinging-insect hypersensitivity 

• Gastrointestinal reactions resulting from allergy, including eosinophilic esophagitis and gastroenteritis 

• Anaphylactic shock

• Immunodeficencies, both congenital and acquired 

• Occupational allergic diseases 

• Identifying and managing risk factors for progression of allergic diseases — the «allergic march» 

• Other specific organ reactions resulting from allergy

• Conditions that may mimic or overlap with allergic disease 

• An expert knowledge of the epidemiology and genetics of allergic diseases Immunodeficencies and autoimmune diseases, with special knowledge of regional and local allergens

As part of the practice of allergy, the allergist should be capable of ordering and interpreting allergy-and immunology-related laboratory tests:

• Evaluating total IgE and allergen specific IgE measurements

• Carrying out appropriate provocation testing for allergic and immunologic disease 

• Providing analysis and advice regarding local environmental/airborne allergens and irritants, as well as the analysis and advice regarding ingested allergens/ irritants

• Conducting and/or evaluating tests of pulmonary function and tests of inflammatory markers

• Conducting and/or evaluating tests of nasal function; this may include examination of nose and throat via fiberoptic rhinoscopy and nasal endoscopy 

• Specific allergen and venom immunotherapy 

• Providing pharmacotherapy of allergic disorders and related diseases including aero-allergens, drugs, venoms, occupational allergens, and food allergens 

Because of the highly specialized training, the allergist can advise both patients and other members of the medical community on:

 The role of effector cells involved in allergic disease (stem cells, • lymphocytes, mast cells, basophils, eosinophils, neutrophils, • monocytes, macrophages, dendritic cells) 

• The molecules involved in the immunological response (both innate and acquired) including chemical mediators; immunoglobulins; antibodies; complement; cytokines;interleukins; chemokines and their receptors; human leukocyte antigen/major histocompatibility complex (HLA/MHC) antigens • The main hypersensitivity reactions 

• Cell-to-cell interactions 

• The scientific in vitro laboratory diagnostic tests for allergy and 

• their selection and interpretation, including allergenspecific in vitro assays; enzyme-linked immunosorbent assays (ELISAs); Western blotting; tests for inflammatory markers, protein and cellular antigen stimulation tests; histamine release assays

The allergist is especially competent in performing/interpreting the following: 

• Allergic history and physical examination 

• Skin testing 

• Where necessary, investigating alternative diagnoses 

• Environmental modification strategies to reduce allergen exposure 

• Specific immunotherapy (allergen vaccines; both oral and injective)

• Immunomodulatory therapy 

• Drug desensitization 

• Evaluation and treatment of allergic and immunologic competence 

• Management and treatment of anaphylactic shock 

• Education for patients, caregivers and primary care physicians 

Physician Tools

Templates to fulfill the documentation requirements for the appropriate level of service are a common resource. They help the physician record sufficient documentation to support the level of medical decision-making required. Templates provide legibility and remind the physician to document encounters legibly and completely. Templates may be in an electronic format or may be in the form of a paper chart. The template can utilize a check-box system as long as the check-box system is uniquely completed for each patient and abnormal findings are described. Many Electronic Medical Record (EMR) systems have built in templates to cross check your work. 

In the future, it may be necessary to provide information to insurance companies for compliance and utilization of medical resources. This documentation may be easier to provide in an electronic format vs. a paper format.

Counseling components: 

• Diagnostic results 

• Prognosis 

• Risks and benefits of treatment options 

• Impressions

• Instructions for management 

• Importance of compliance with chosen treatment options 

• Risk factor reductions 

• Patient and family education

Medical Decision-Making

Medical decision-making coding includes the number of diagnoses and treatment options, the amount of data and the complexity of data and risk.

Diagnosis and treatment options: 

• New problem – a problem new to the physician 

• Established problem, stable – a known diagnosis that is stable 

• Established problem, worsening – a known diagnosis that is worse 

• Established problem, improved – a known diagnosis that has improved 

• Work-up planned – a new complaint for which additional work-up is planned 

• No work-up planned – new complaint(s) for which no additional work-up is planned

Coding for the amount and complexity of data component is composed of the following information, which is obtained, ordered or reviewed during the encounter:

• Review/order lab tests 

• Review/order routine x-rays 

• Review/order test from medicine section 

• Discuss test results with performing physician 

• Decide to obtain old records and documents 

• Document direct visualization and independent interpretation

The risk component is composed of the present problem, diagnostic procedure or management option. The risk is determined by the component of the highest level to determine the overall risk for the patient.

Presenting problems are described as: 

• Minimal – one self-limited or minor problem 

• Low – two or more self-limited or minor problems, one stable chronic illness or one acute uncomplicated illness/injury 

• Moderate – one or more chronic illness with mild exacerbation, two or more stable chronic illnesses, undiagnosed new problem with uncertain prognosis, acute illness with systemic symptoms or acute complicated injury 

• High – chronic illness with severe exacerbation or acute or chronic illness/injury that may pose a threat to life or bodily function

The component for diagnostic procedures ordered is described as: 

• Minimal – lab tests requiring venipuncture, x-rays, ultrasound 

• Low – superficial needle biopsies, skin biopsies, PFTs

• Moderate – diagnostic endoscopy, deep needle or incisional biopsy 

• High – diagnostic endoscopy with risk factors

Management options are described as:

 • Minimal – rest, gargles, elastic/superficial dressings

 • Low – over-the-counter drugs, saline washes, minor surgery, physical therapy

 • Moderate – minor surgery with risk, elective major surgery, prescription drug management

 • High – elective major surgery with risk, emergency major surgery, decision not to resuscitate or de-escalate care because of poor prognosis, drug therapy requiring intensive monitoring for toxicity, high morbidity and mortality without treatment

The level of medical decision-making depends on the number of diagnoses, the amount and complexity of the data and the risk. The appropriate level is determined by choosing the level where the middle component rests, or where two out of three of the components meet. For example, a new patient presents with asthma and allergic rhinitis. The patient is allergy tested, has a PFT and is placed on a prescription medication. The appropriate level of medical decision-making would be moderate for this patient. If a comprehensive history and a comprehensive exam were also performed and documented, the physician would code for a 99204 level of service.

ICD-10 CM Codes that support Medical Necessity for CPT Code 86003 Part 03

T41.45XS Adverse effect of unspecified anesthetic, sequela
T41.45XD Adverse effect of unspecified anesthetic, subsequent encounter
T43.205A Adverse effect of unspecified antidepressants, initial encounter
T43.205S Adverse effect of unspecified antidepressants, sequela
T43.205D Adverse effect of unspecified antidepressants, subsequent encounter
T42.75XA Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XS Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, sequela
T42.75XD Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
T43.505A Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.505S Adverse effect of unspecified antipsychotics and neuroleptics, sequela
T43.505D Adverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter
T48.205A Adverse effect of unspecified drugs acting on muscles, initial encounter
T48.205S Adverse effect of unspecified drugs acting on muscles, sequela
T48.205D Adverse effect of unspecified drugs acting on muscles, subsequent encounter
T44.905A Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.905S Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.905D Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T50.905A Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.905S Adverse effect of unspecified drugs, medicaments and biological substances, sequela
T50.905D Adverse effect of unspecified drugs, medicaments and biological substances, subsequent encounter
T45.605A Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
T45.605S Adverse effect of unspecified fibrinolysis-affecting drugs, sequela
T45.605D Adverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter
T41.205A Adverse effect of unspecified general anesthetics, initial encounter
T41.205S Adverse effect of unspecified general anesthetics, sequela
T41.205D Adverse effect of unspecified general anesthetics, subsequent encounter
T38.905A Adverse effect of unspecified hormone antagonists, initial encounter
T38.905S Adverse effect of unspecified hormone antagonists, sequela
T38.905D Adverse effect of unspecified hormone antagonists, subsequent encounter
T38.805A Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
T38.805S Adverse effect of unspecified hormones and synthetic substitutes, sequela
T38.805D Adverse effect of unspecified hormones and synthetic substitutes, subsequent encounter
T40.605A Adverse effect of unspecified narcotics, initial encounter
T40.605S Adverse effect of unspecified narcotics, sequela
T40.605D Adverse effect of unspecified narcotics, subsequent encounter
T39.95XA Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
T39.95XS Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
T39.95XD Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
T45.95XA Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T45.95XS Adverse effect of unspecified primarily systemic and hematological agent, sequela
T45.95XD Adverse effect of unspe
T40.905A Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.905S Adverse effect of unspecified psychodysleptics [hallucinogens], sequela
T40.905D Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter
T43.605A Adverse effect of unspecified psychostimulants, initial encounter
T43.605S Adverse effect of unspecified psychostimulants, sequela
T43.605D Adverse effect of unspecified psychostimulants, subsequent encounter
T43.95XA Adverse effect of unspecified psychotropic drug, initial encounter
T43.95XS Adverse effect of unspecified psychotropic drug, sequela
T43.95XD Adverse effect of unspecified psychotropic drug, subsequent encounter
T36.95XA Adverse effect of unspecified systemic antibiotic, initial encounter
T36.95XS Adverse effect of unspecified systemic antibiotic, sequela
T36.95XD Adverse effect of unspecified systemic antibiotic, subsequent encounter
T37.95XA Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T37.95XS Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela
T37.95XD Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter
T49.95XA Adverse effect of unspecified topical agent, initial encounter
T49.95XS Adverse effect of unspecified topical agent, sequela
T49.95XD Adverse effect of unspecified topical agent, subsequent encounter
T45.2X5A Adverse effect of vitamins, initial encounter
T45.2X5S Adverse effect of vitamins, sequela
T45.2X5D Adverse effect of vitamins, subsequent encounter
B44.81 Allergic bronchopulmonary aspergillosis
L23.9 Allergic contact dermatitis, unspecified cause
J30.81 Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.5 Allergic rhinitis due to food
J30.1 Allergic rhinitis due to pollen
L50.0 Allergic urticaria
Z88.6 Allergy status to analgesic agent status
Z88.4 Allergy status to anesthetic agent status
Z88.5 Allergy status to narcotic agent status
Z88.1 Allergy status to other antibiotic agents status
Z88.3 Allergy status to other anti-infective agents status
Z88.8 Allergy status to other drugs, medicaments and biological substances status
Z88.0 Allergy status to penicillin
Z88.7 Allergy status to serum and vaccine status
Z88.2 Allergy status to sulfonamides status
Z91.012 Allergy to eggs
Z91.011 Allergy to milk products
Z91.018 Allergy to other foods
Z91.010 Allergy to peanuts
Z91.013 Allergy to seafood
T78.40XA Allergy, unspecified, initial encounter
T80.51XA Anaphylactic reaction due to administration of blood and blood products, initial encounter
T88.6XXA Anaphylactic reaction due to adverse effect of correct drug or medicament
properly administered, initial encounter
T78.08XA Anaphylactic reaction due to eggs, initial encounter
T78.06XA Anaphylactic reaction due to food additives, initial encounter
T78.04XA Anaphylactic reaction due to fruits and vegetables, initial encounter
T78.07XA Anaphylactic reaction due to milk and dairy products, initial encounter
T78.03XA Anaphylactic reaction due to other fish, initial encounter
T78.09XA Anaphylactic reaction due to other food products, initial encounter
T80.59XA Anaphylactic reaction due to other serum, initial encounter
T78.01XA Anaphylactic reaction due to peanuts, initial encounter
T78.02XA Anaphylactic reaction due to shellfish (crustaceans), initial encounter
T78.05XA Anaphylactic reaction due to tree nuts and seeds, initial encounter
T78.00XA Anaphylactic reaction due to unspecified food, initial encounter
T80.52XA Anaphylactic reaction due to vaccination, initial encounter
T78.2XXA Anaphylactic shock, unspecified, initial encounter
T78.3XXA Angioneurotic edema, initial encounter
R43.0 Anosmia
L20.81 Atopic neurodermatitis
L20.0 Besnier’s prurigo
J35.02 Chronic adenoiditis
H65.413 Chronic allergic otitis media, bilateral
H65.412 Chronic allergic otitis media, left ear
H65.411 Chronic allergic otitis media, right ear
J32.2 Chronic ethmoidal sinusitis
H68.023 Chronic Eustachian salpingitis, bilateral
H68.022 Chronic Eustachian salpingitis, left ear
H68.021 Chronic Eustachian salpingitis, right ear
J32.1 Chronic frontal sinusitis
H10.413 Chronic giant papillary conjunctivitis, bilateral
H10.412 Chronic giant papillary conjunctivitis, left eye
H10.411 Chronic giant papillary conjunctivitis, right eye
J32.0 Chronic maxillary sinusitis
J31.1 Chronic nasopharyngitis
J31.2 Chronic pharyngitis
J31.0 Chronic rhinitis
H65.23 Chronic serous otitis media, bilateral
H65.22 Chronic serous otitis media, left ear
H65.21 Chronic serous otitis media, right ear
J32.3 Chronic sphenoidal sinusitis
K29.30 Chronic superficial gastritis without bleeding
J35.01 Chronic tonsillitis
J35.03 Chronic tonsillitis and adenoiditis
L50.6 Contact urticaria
R05 Cough
J45.991 Cough variant asthma
L30.2 Cutaneous autosensitization
L27.2 Dermatitis due to ingested food
L27.8 Dermatitis due to other substances taken internally
L27.9 Dermatitis due to unspecified substance taken internally
L50.3 Dermatographic urticaria
L20.82 Flexural eczema
L27.0 Generalized skin eruption due to drugs and medicaments taken internally
J35.2 Hypertrophy of adenoids
J34.3 Hypertrophy of nasal turbinates
J35.1 Hypertrophy of tonsils
J35.3 Hypertrophy of tonsils with hypertrophy of adenoids
L50.1 Idiopathic urticaria
L20.84 Intrinsic (allergic) eczema
L24.9 Irritant contact dermatitis, unspecified cause
L27.1 Localized skin eruption due to drugs and medicaments taken internally
J45.21 Mild intermittent asthma with (acute) exacerbation
J45.22 Mild intermittent asthma with status asthmaticus
J45.20 Mild intermittent asthma, uncomplicated
J45.31 Mild persistent asthma with (acute) exacerbation
J45.32 Mild persistent asthma with status asthmaticus
J45.30 Mild persistent asthma, uncomplicated
J45.41 Moderate persistent asthma with (acute) exacerbation
J45.42 Moderate persistent asthma with status asthmaticus
J45.40 Moderate persistent asthma, uncomplicated
R09.81 Nasal congestion
J34.81 Nasal mucositis (ulcerative)
L30.0 Nummular dermatitis
J01.81 Other acute recurrent sinusitis
J01.80 Other acute sinusitis
T78.1XXA Other adverse food reactions, not elsewhere classified, initial encounter
J30.89 Other allergic rhinitis
Z91.09 Other allergy status, other than to drugs and biological substances
T78.49XA Other allergy, initial encounter
J45.998 Other asthma
L20.89 Other atopic dermatitis
H10.45 Other chronic allergic conjunctivitis
H65.493 Other chronic nonsuppurative otitis media, bilateral
H65.492 Other chronic nonsuppurative otitis media, left ear
H65.491 Other chronic nonsuppurative otitis media, right ear
R43.8 Other disturbances of smell and taste
R06.09 Other forms of dyspnea
K29.60 Other gastritis without bleeding
Z91.048 Other nonmedicinal substance allergy status
J33.8 Other polyp of sinus
J30.2 Other seasonal allergic rhinitis
T80.61XA Other serum reaction due to administration of blood and blood products, initial encounter
T80.69XA Other serum reaction due to other serum, initial encounter
T80.62XA Other serum reaction due to vaccination, initial encounter
L30.8 Other specified dermatitis
J34.89 Other specified disorders of nose and nasal sinuses
L50.8 Other urticaria
H66.93 Otitis media, unspecified, bilateral
H66.92 Otitis media, unspecified, left ear
H66.91 Otitis media, unspecified, right ear
R43.2 Parageusia
R43.1 Parosmia
T39.1X1A Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter
T39.1X1S Poisoning by 4-Aminophenol derivatives, accidental (unintentional), sequela
T39.1X1D Poisoning by 4-Aminophenol derivatives, accidental (unintentional), subsequent encounter
T39.1X3A Poisoning by 4-Aminophenol derivatives, assault, initial encounter
T39.1X3S Poisoning by 4-Aminophenol derivatives, assault, sequela
T39.1X3D Poisoning by 4-Aminophenol derivatives, assault, subsequent encounter
T39.1X2A Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
T39.1X2S Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela
T39.1X2D Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter
T39.1X4A Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter
T39.1X4S Poisoning by 4-Aminophenol derivatives, undetermined, sequela
T39.1X4D Poisoning by 4-Aminophenol derivatives, undetermined, subsequent encounter
T44.6X1A Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), initial encounter
T44.6X1S Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), sequela
T44.6X1D Poisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
T44.6X3A Poisoning by alpha-adrenoreceptor antagonists, assault, initial encounter
T44.6X3S Poisoning by alpha-adrenoreceptor antagonists, assault, sequela
T44.6X3D Poisoning by alpha-adrenoreceptor antagonists, assault, subsequent encounter
T44.6X2A Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter
T44.6X2S Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela
T44.6X2D Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T44.6X4A Poisoning by alpha-adrenoreceptor antagonists, undetermined, initial encounter
T44.6X4S Poisoning by alpha-adrenoreceptor antagonists, undetermined, sequela
T44.6X4D Poisoning by alpha-adrenoreceptor antagonists, undetermined, subsequent encounter
T36.5X1A Poisoning by aminoglycosides, accidental (unintentional), initial encounter
T36.5X1S Poisoning by aminoglycosides, accidental (unintentional), sequela
T36.5X1D Poisoning by aminoglycosides, accidental (unintentional), subsequent encounter
T36.5X3A Poisoning by aminoglycosides, assault, initial encounter
T36.5X3S Poisoning by aminoglycosides, assault, sequela
T36.5X3D Poisoning by aminoglycosides, assault, subsequent encounter
T36.5X2A Poisoning by aminoglycosides, intentional self-harm, initial encounter
T36.5X2S Poisoning by aminoglycosides, intentional self-harm, sequela
T36.5X2D Poisoning by aminoglycosides, intentional self-harm, subsequent encounter
T36.5X4A Poisoning by aminoglycosides, undetermined, initial encounter
T36.5X4S Poisoning by aminoglycosides, undetermined, sequela
T36.5X4D Poisoning by aminoglycosides, undetermined, subsequent encounter
T43.621A Poisoning by amphetamines, accidental (unintentional), initial encounter
T43.621S Poisoning by amphetamines, accidental (unintentional), sequela
T43.621D Poisoning by amphetamines, accidental (unintentional), subsequent encounter
T43.623A Poisoning by amphetamines, assault, initial encounter
T43.623S Poisoning by amphetamines, assault, sequela
T43.623D Poisoning by amphetamines, assault, subsequent encounter
T43.622A Poisoning by amphetamines, intentional self-harm, initial encounter
T43.622S Poisoning by amphetamines, intentional self-harm, sequela
T43.622D Poisoning by amphetamines, intentional self-harm, subsequent encounter
T43.624A Poisoning by amphetamines, undetermined, initial encounter
T43.624S Poisoning by amphetamines, undetermined, sequela
T43.624D Poisoning by amphetamines, undetermined, subsequent encounter
T50.7X1A Poisoning by analeptics and opioid receptor antagonists, accidental (unintentional), initial encounter
T50.7X1S Poisoning by analeptics and opioid receptor antagonists, accidental (unintentional), sequela
T50.7X1D Poisoning by analeptics and opioid receptor antagonists, accidental (unintentional), subsequent encounter
T50.7X3A Poisoning by analeptics and opioid receptor antagonists, assault, initial encounter
T50.7X3S Poisoning by analeptics and opioid receptor antagonists, assault, sequela
T50.7X3D Poisoning by analeptics and opioid receptor antagonists, assault, subsequent encounter
T50.7X2A Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter
T50.7X2S Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela
T50.7X2D Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter
T50.7X4A Poisoning by analeptics and opioid receptor antagonists, undetermined, initial encounter
T50.7X4S Poisoning by analeptics and opioid receptor antagonists, undetermined, sequela
T50.7X4D Poisoning by analeptics and opioid receptor antagonists, undetermined, subsequent encounter
T38.7X1A Poisoning by androgens and anabolic congeners, accidental (unintentional), initial encounter
T38.7X1S Poisoning by androgens and anabolic congeners, accidental (unintentional), sequela
T38.7X1D Poisoning by androgens and anabolic congeners, accidental (unintentional), subsequent encounter
T38.7X3A Poisoning by androgens and anabolic congeners, assault, initial encounter
T38.7X3S Poisoning by androgens and anabolic congeners, assault, sequela
T38.7X3D Poisoning by androgens and anabolic congeners, assault, subsequent encounter
T38.7X2A Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter
T38.7X2S Poisoning by androgens and anabolic congeners, intentional self-harm, sequela
T38.7X2D Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter
T38.7X4A Poisoning by androgens and anabolic congeners, undetermined, initial encounter
T38.7X4S Poisoning by androgens and anabolic congeners, undetermined, sequela
T38.7X4D Poisoning by androgens and anabolic congeners, undetermined, subsequent encounter
T46.4X1A Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), initial encounter
T46.4X1S Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), sequela
T46.4X1D Poisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), subsequent encounter
T46.4X3A Poisoning by angiotensin-converting-enzyme inhibitors, assault, initial encounter
T46.4X3S Poisoning by angiotensin-converting-enzyme inhibitors, assault, sequela
T46.4X3D Poisoning by angiotensin-converting-enzyme inhibitors, assault, subsequent encounter
T46.4X2A Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter
T46.4X2S Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela
T46.4X2D Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter
T46.4X4A Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, initial encounter
T46.4X4S Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, sequela
T46.4X4D Poisoning by angiotensin-converting-enzyme inhibitors, undetermined, subsequent encounter
T38.811A Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), initial encounter
T38.811S Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), sequela
T38.811D Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), subsequent encounter
T38.813A Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, initial encounter
T38.813S Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, sequela
T38.813D Poisoning by anterior pituitary [adenohypophyseal] hormones, assault, subsequent encounter
T38.812A Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional selfharm, initial encounter
T38.812S Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional selfharm, sequela
T38.812D Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional selfharm, subsequent encounter
T38.814A Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, initial encounter
T38.814S Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, sequela
T38.814D Poisoning by anterior pituitary [adenohypophyseal] hormones, undetermined, subsequent encounter
T37.4X1A Poisoning by anthelminthics, accidental (unintentional), initial encounter
T37.4X1S Poisoning by anthelminthics, accidental (unintentional), sequela
T37.4X1D Poisoning by anthelminthics, accidental (unintentional), subsequent encounter
T37.4X3A Poisoning by anthelminthics, assault, initial encounter
T37.4X3S Poisoning by anthelminthics, assault, sequela
T37.4X3D Poisoning by anthelminthics, assault, subsequent encounter
T37.4X2A Poisoning by anthelminthics, intentional self-harm, initial encounter
T37.4X2S Poisoning by anthelminthics, intentional self-harm, sequela
T37.4X2D Poisoning by anthelminthics, intentional self-harm, subsequent encounter
T37.4X4A Poisoning by anthelminthics, undetermined, initial encounter
T37.4X4S Poisoning by anthelminthics, undetermined, sequela
T37.4X4D Poisoning by anthelminthics, undetermined, subsequent encounter
T45.0X1A Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter
T45.0X1S Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), sequela
T45.0X1D Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), subsequent encounter
T45.0X3A Poisoning by antiallergic and antiemetic drugs, assault, initial encounter
T45.0X3S Poisoning by antiallergic and antiemetic drugs, assault, sequela
T45.0X3D Poisoning by antiallergic and antiemetic drugs, assault, subsequent encounter
T45.0X2A Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter
T45.0X2S Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela
T45.0X2D Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter
T45.0X4A Poisoning by antiallergic and antiemetic drugs, undetermined, initial encounter
T45.0X4S Poisoning by antiallergic and antiemetic drugs, undetermined, sequela
T45.0X4D Poisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter
T48.6X1A Poisoning by antiasthmatics, accidental (unintentional), initial encounter
T48.6X1S Poisoning by antiasthmatics, accidental (unintentional), sequela
T48.6X1D Poisoning by antiasthmatics, accidental (unintentional), subsequent encounter
T48.6X3A Poisoning by antiasthmatics, assault, initial encounter
T48.6X3S Poisoning by antiasthmatics, assault, sequela
T48.6X3D Poisoning by antiasthmatics, assault, subsequent encounter
T48.6X2A Poisoning by antiasthmatics, intentional self-harm, initial encounter
T48.6X2S Poisoning by antiasthmatics, intentional self-harm, sequela
T48.6X2D Poisoning by antiasthmatics, intentional self-harm, subsequent encounter
T48.6X4A Poisoning by antiasthmatics, undetermined, initial encounter
T48.6X4S Poisoning by antiasthmatics, undetermined, sequela
T48.6X4D Poisoning by antiasthmatics, undetermined, subsequent encounter
T44.0X1A Poisoning by anticholinesterase agents, accidental (unintentional), initial encounter
T44.0X1S Poisoning by anticholinesterase agents, accidental (unintentional), sequela
T44.0X1D Poisoning by anticholinesterase agents, accidental (unintentional), subsequent encounter
T44.0X3A Poisoning by anticholinesterase agents, assault, initial encounter
T44.0X3S Poisoning by anticholinesterase agents, assault, sequela
T44.0X3D Poisoning by anticholinesterase agents, assault, subsequent encounter
T44.0X2A Poisoning by anticholinesterase agents, intentional self-harm, initial encounter
T44.0X2S Poisoning by anticholinesterase agents, intentional self-harm, sequela
T44.0X2D Poisoning by anticholinesterase agents, intentional self-harm, subsequent
encounter
T44.0X4A Poisoning by anticholinesterase agents, undetermined, initial encounter
T44.0X4S Poisoning by anticholinesterase agents, undetermined, sequela
T44.0X4D Poisoning by anticholinesterase agents, undetermined, subsequent encounter
T45.7X1A Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), initial encounter
T45.7X1S Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), sequela
T45.7X1D Poisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), subsequent encounter
T45.7X3A Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, initial encounter
T45.7X3S Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, sequela
T45.7X3D Poisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, subsequent encounter
T45.7X2A Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter
T45.7X2S Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela
T45.7X2D Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter
T45.7X4A Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, initial encounter
T45.7X4S Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, sequela
T45.7X4D Poisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, subsequent encounter
T45.511A Poisoning by anticoagulants, accidental (unintentional), initial encounter
T45.511S Poisoning by anticoagulants, accidental (unintentional), sequela
T45.511D Poisoning by anticoagulants, accidental (unintentional), subsequent encounter
T45.513A Poisoning by anticoagulants, assault, initial encounter
T45.513S Poisoning by anticoagulants, assault, sequela
T45.513D Poisoning by anticoagulants, assault, subsequent encounter
T45.512A Poisoning by anticoagulants, intentional self-harm, initial encounter
T45.512S Poisoning by anticoagulants, intentional self-harm, sequela
T45.512D Poisoning by anticoagulants, intentional self-harm, subsequent encounter
T45.514A Poisoning by anticoagulants, undetermined, initial encounter
T45.514S Poisoning by anticoagulants, undetermined, sequela
T45.514D Poisoning by anticoagulants, undetermined, subsequent encounter
T47.6X1A Poisoning by antidiarrheal drugs, accidental (unintentional), initial encounter
T47.6X1S Poisoning by antidiarrheal drugs, accidental (unintentional), sequela
T47.6X1D Poisoning by antidiarrheal drugs, accidental (unintentional), subsequent encounter
T47.6X3A Poisoning by antidiarrheal drugs, assault, initial encounter
T47.6X3S Poisoning by antidiarrheal drugs, assault, sequela
T47.6X3D Poisoning by antidiarrheal drugs, assault, subsequent encounter
T47.6X2A Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter
T47.6X2S Poisoning by antidiarrheal drugs, intentional self-harm, sequela
T47.6X2D Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter
T47.6X4A Poisoning by antidiarrheal drugs, undetermined, initial encounter

ICD-10 CM Codes that support Medical Necessity for CPT Code 86003 Part 02

T36.3X5A Adverse effect of macrolides, initial encounter
T36.3X5S Adverse effect of macrolides, sequela
T36.3X5D Adverse effect of macrolides, subsequent encounter
T40.3X5A Adverse effect of methadone, initial encounter
T40.3X5S Adverse effect of methadone, sequela
T40.3X5D Adverse effect of methadone, subsequent encounter
T43.635A Adverse effect of methylphenidate, initial encounter
T43.635S Adverse effect of methylphenidate, sequela
T43.635D Adverse effect of methylphenidate, subsequent encounter
T50.0X5A Adverse effect of mineralocorticoids and their antagonists, initial encounter
T50.0X5S Adverse effect of mineralocorticoids and their antagonists, sequela
T50.0X5D Adverse effect of mineralocorticoids and their antagonists, subsequent encounter
T42.5X5A Adverse effect of mixed antiepileptics, initial encounter
T42.5X5S Adverse effect of mixed antiepileptics, sequela
T42.5X5D Adverse effect of mixed antiepileptics, subsequent encounter
T50.A25A Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
T50.A25S Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
T50.A25D Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter
T43.1X5A Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.1X5S Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
T43.1X5D Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
T49.5X5A Adverse effect of ophthalmological drugs and preparations, initial encounter
T49.5X5S Adverse effect of ophthalmological drugs and preparations, sequela
T49.5X5D Adverse effect of ophthalmological drugs and preparations, subsequent encounter
T40.0X5A Adverse effect of opium, initial encounter
T40.0X5S Adverse effect of opium, sequela
T40.0X5D Adverse effect of opium, subsequent encounter
T38.4X5A Adverse effect of oral contraceptives, initial encounter
T38.4X5S Adverse effect of oral contraceptives, sequela
T38.4X5D Adverse effect of oral contraceptives, subsequent encounter
T48.995A Adverse effect of other agents primarily acting on the respiratory system, initial encounter
T48.995S Adverse effect of other agents primarily acting on the respiratory system, sequela
T48.995D Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter
T47.8X5A Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
T47.8X5S Adverse effect of other agents primarily affecting gastrointestinal system, sequela
T47.8X5D Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter
T46.995A Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
T46.995S Adverse effect of other agents primarily affecting the cardiovascular system, sequela
T46.995D Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
T47.1X5A Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
T47.1X5S Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
T47.1X5D Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
T48.5X5A Adverse effect of other anti-common-cold drugs, initial encounter
T48.5X5S Adverse effect of other anti-common-cold drugs, sequela
T48.5X5D Adverse effect of other anti-common-cold drugs, subsequent encounter
T43.295A Adverse effect of other antidepressants, initial encounter
T43.295S Adverse effect of other antidepressants, sequela
T43.295D Adverse effect of other antidepressants, subsequent encounter
T46.2X5A Adverse effect of other antidysrhythmic drugs, initial encounter
T46.2X5S Adverse effect of other antidysrhythmic drugs, sequela
T46.2X5D Adverse effect of other antidysrhythmic drugs, subsequent encounter
T42.6X5A Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.6X5S Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
T42.6X5D Adverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
T46.5X5A Adverse effect of other antihypertensive drugs, initial encounter
T46.5X5S Adverse effect of other antihypertensive drugs, sequela
T46.5X5D Adverse effect of other antihypertensive drugs, subsequent encounter
T37.3X5A Adverse effect of other antiprotozoal drugs, initial encounter
T37.3X5S Adverse effect of other antiprotozoal drugs, sequela
T37.3X5D Adverse effect of other antiprotozoal drugs, subsequent encounter
T43.595A Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.595S Adverse effect of other antipsychotics and neuroleptics, sequela
T43.595D Adverse effect of other antipsychotics and neuroleptics, subsequent encounter
T50.A95A Adverse effect of other bacterial vaccines, initial encounter
T50.A95S Adverse effect of other bacterial vaccines, sequela
T50.A95D Adverse effect of other bacterial vaccines, subsequent encounter
T44.995A Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T44.995S Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
T44.995D Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
T48.295A Adverse effect of other drugs acting on muscles, initial encounter
T48.295S Adverse effect of other drugs acting on muscles, sequela
T48.295D Adverse effect of other drugs acting on muscles, subsequent encounter
T50.995A Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.995S Adverse effect of other drugs, medicaments and biological substances, sequela
T50.995D Adverse effect of other drugs, medicaments and biological substances, subsequent encounter
T38.5X5A Adverse effect of other estrogens and progestogens, initial encounter
T38.5X5S Adverse effect of other estrogens and progestogens, sequela
T38.5X5D Adverse effect of other estrogens and progestogens, subsequent encounter
T45.695A Adverse effect of other fibrinolysis-affecting drugs, initial encounter
T45.695S Adverse effect of other fibrinolysis-affecting drugs, sequela
T45.695D Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter
T41.295A Adverse effect of other general anesthetics, initial encounter
T41.295S Adverse effect of other general anesthetics, sequela
T41.295D Adverse effect of other general anesthetics, subsequent encounter
T38.995A Adverse effect of other hormone antagonists, initial encounter
T38.995S Adverse effect of other hormone antagonists, sequela
T38.995D Adverse effect of other hormone antagonists, subsequent encounter
T38.895A Adverse effect of other hormones and synthetic substitutes, initial encounter
T38.895S Adverse effect of other hormones and synthetic substitutes, sequela
T38.895D Adverse effect of other hormones and synthetic substitutes, subsequent encounter
T47.4X5A Adverse effect of other laxatives, initial encounter
T47.4X5S Adverse effect of other laxatives, sequela
T47.4X5D Adverse effect of other laxatives, subsequent encounter
T40.695A Adverse effect of other narcotics, initial encounter
T40.695S Adverse effect of other narcotics, sequela
T40.695D Adverse effect of other narcotics, subsequent encounter
T39.8X5A Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
T39.8X5S Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
T39.8X5D Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
T39.395A Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.395S Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
T39.395D Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
T40.2X5A Adverse effect of other opioids, initial encounter
T40.2X5S Adverse effect of other opioids, sequela
T40.2X5D Adverse effect of other opioids, subsequent encounter
T44.3X5A Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X5S Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.3X5D Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.1X5A Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.1X5S Adverse effect of other parasympathomimetics [cholinergics], sequela
T44.1X5D Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter
T45.8X5A Adverse effect of other primarily systemic and hematological agents, initial encounter
T45.8X5S Adverse effect of other primarily systemic and hematological agents, sequela
T45.8X5D Adverse effect of other primarily systemic and hematological agents, subsequent encounter
T40.995A Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T40.995S Adverse effect of other psychodysleptics [hallucinogens], sequela
T40.995D Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter
T43.695A Adverse effect of other psychostimulants, initial encounter
T43.695S Adverse effect of other psychostimulants, sequela
T43.695D Adverse effect of other psychostimulants, subsequent encounter
T43.8X5A Adverse effect of other psychotropic drugs, initial encounter
T43.8X5S Adverse effect of other psychotropic drugs, sequela
T43.8X5D Adverse effect of other psychotropic drugs, subsequent encounter
T37.8X5A Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
T37.8X5S Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela
T37.8X5D Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter
T40.4X5A Adverse effect of other synthetic narcotics, initial encounter
T40.4X5S Adverse effect of other synthetic narcotics, sequela
T40.4X5D Adverse effect of other synthetic narcotics, subsequent encounter
T36.8X5A Adverse effect of other systemic antibiotics, initial encounter
T36.8X5S Adverse effect of other systemic antibiotics, sequela
T36.8X5D Adverse effect of other systemic antibiotics, subsequent encounter
T49.8X5A Adverse effect of other topical agents, initial encounter
T49.8X5S Adverse effect of other topical agents, sequela
T49.8X5D Adverse effect of other topical agents, subsequent encounter
T50.Z95A Adverse effect of other vaccines and biological substances, initial encounter
T50.Z95S Adverse effect of other vaccines and biological substances, sequela
T50.Z95D Adverse effect of other vaccines and biological substances, subsequent encounter
T50.B95A Adverse effect of other viral vaccines, initial encounter
T50.B95S Adverse effect of other viral vaccines, sequela
T50.B95D Adverse effect of other viral vaccines, subsequent encounter
T49.6X5A Adverse effect of otorhinolaryngological drugs and preparations, initial encounter
T49.6X5S Adverse effect of otorhinolaryngological drugs and preparations, sequela
T49.6X5D Adverse effect of otorhinolaryngological drugs and preparations, subsequent encounter
T48.0X5A Adverse effect of oxytocic drugs, initial encounter
T48.0X5S Adverse effect of oxytocic drugs, sequela
T48.0X5D Adverse effect of oxytocic drugs, subsequent encounter
T36.0X5A Adverse effect of penicillins, initial encounter
T36.0X5S Adverse effect of penicillins, sequela
T36.0X5D Adverse effect of penicillins, subsequent encounter
T46.7X5A Adverse effect of peripheral vasodilators, initial encounter
T46.7X5S Adverse effect of peripheral vasodilators, sequela
T46.7X5D Adverse effect of peripheral vasodilators, subsequent encounter
T50.A15A Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
T50.A15S Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
T50.A15D Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter
T43.3X5A Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.3X5S Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
T43.3X5D Adverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T44.4X5A Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X5S Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.4X5D Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.5X5A Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X5S Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.5X5D Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
T39.315A Adverse effect of propionic acid derivatives, initial encounter
T39.315S Adverse effect of propionic acid derivatives, sequela
T39.315D Adverse effect of propionic acid derivatives, subsequent encounter
T39.2X5A Adverse effect of pyrazolone derivatives, initial encounter
T39.2X5S Adverse effect of pyrazolone derivatives, sequela
T39.2X5D Adverse effect of pyrazolone derivatives, subsequent encounter
T36.6X5A Adverse effect of rifampicins, initial encounter
T36.6X5S Adverse effect of rifampicins, sequela
T36.6X5D Adverse effect of rifampicins, subsequent encounter
T39.095A Adverse effect of salicylates, initial encounter
T39.095S Adverse effect of salicylates, sequela
T39.095D Adverse effect of salicylates, subsequent encounter
T47.3X5A Adverse effect of saline and osmotic laxatives, initial encounter
T47.3X5S Adverse effect of saline and osmotic laxatives, sequela
T47.3X5D Adverse effect of saline and osmotic laxatives, subsequent encounter
T43.215A Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.215S Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
T43.215D Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
T43.225A Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.225S Adverse effect of selective serotonin reuptake inhibitors, sequela
T43.225D Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter
T48.1X5A Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
T48.1X5S Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
T48.1X5D Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
T50.B15A Adverse effect of smallpox vaccines, initial encounter
T50.B15S Adverse effect of smallpox vaccines, sequela
T50.B15D Adverse effect of smallpox vaccines, subsequent encounter
T47.2X5A Adverse effect of stimulant laxatives, initial encounter
T47.2X5S Adverse effect of stimulant laxatives, sequela
T47.2X5D Adverse effect of stimulant laxatives, subsequent encounter
T42.2X5A Adverse effect of succinimides and oxazolidinediones, initial encounter
T42.2X5S Adverse effect of succinimides and oxazolidinediones, sequela
T42.2X5D Adverse effect of succinimides and oxazolidinediones, subsequent encounter
T37.0X5A Adverse effect of sulfonamides, initial encounter
T37.0X5S Adverse effect of sulfonamides, sequela
T37.0X5D Adverse effect of sulfonamides, subsequent encounter
T43.025A Adverse effect of tetracyclic antidepressants, initial encounter
T43.025S Adverse effect of tetracyclic antidepressants, sequela
T43.025D Adverse effect of tetracyclic antidepressants, subsequent encounter
T36.4X5A Adverse effect of tetracyclines, initial encounter
T36.4X5S Adverse effect of tetracyclines, sequela
T36.4X5D Adverse effect of tetracyclines, subsequent encounter
T41.5X5A Adverse effect of therapeutic gases, initial encounter
T41.5X5S Adverse effect of therapeutic gases, sequela
T41.5X5D Adverse effect of therapeutic gases, subsequent encounter
T45.615A Adverse effect of thrombolytic drugs, initial encounter
T45.615S Adverse effect of thrombolytic drugs, sequela
T45.615D Adverse effect of thrombolytic drugs, subsequent encounter
T38.1X5A Adverse effect of thyroid hormones and substitutes, initial encounter
T38.1X5S Adverse effect of thyroid hormones and substitutes, sequela
T38.1X5D Adverse effect of thyroid hormones and substitutes, subsequent encounter
T43.015A Adverse effect of tricyclic antidepressants, initial encounter
T43.015S Adverse effect of tricyclic antidepressants, sequela
T43.015D Adverse effect of tricyclic antidepressants, subsequent encounter
T48.905A Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
T48.905S Adverse effect of unspecified agents primarily acting on the respiratory system, sequela
T48.905D Adverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter
T46.905A Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46.905S Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
T46.905D Adverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
T47.95XA Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
T47.95XS Adverse effect of unspecified agents primarily affecting the gastrointestinal system, sequela
T47.95XD Adverse effect of unspecified agents primarily affecting the gastrointestinal system, subsequent encounter
T41.45XA Adverse effect of unspecified anesthetic, initial encounter

ICD-10 CM Codes that support Medical Necessity for CPT Code 86003 Part 01

H10.13 Acute atopic conjunctivitis, bilateral
H10.12 Acute atopic conjunctivitis, left eye
H10.11 Acute atopic conjunctivitis, right eye
J01.20 Acute ethmoidal sinusitis, unspecified
H68.013 Acute Eustachian salpingitis, bilateral
H68.012 Acute Eustachian salpingitis, left ear
H68.011 Acute Eustachian salpingitis, right ear
J01.10 Acute frontal sinusitis, unspecified
J04.0 Acute laryngitis
J01.00 Acute maxillary sinusitis, unspecified
J05.0 Acute obstructive laryngitis [croup]
J01.40 Acute pansinusitis, unspecified
J01.21 Acute recurrent ethmoidal sinusitis
J01.11 Acute recurrent frontal sinusitis
J01.01 Acute recurrent maxillary sinusitis
J01.41 Acute recurrent pansinusitis
J01.91 Acute recurrent sinusitis, unspecified
J01.31 Acute recurrent sphenoidal sinusitis
H65.03 Acute serous otitis media, bilateral
H65.02 Acute serous otitis media, left ear
H65.06 Acute serous otitis media, recurrent, bilateral
H65.05 Acute serous otitis media, recurrent, left ear
H65.04 Acute serous otitis media, recurrent, right ear
H65.01 Acute serous otitis media, right ear
J01.90 Acute sinusitis, unspecified
J01.30 Acute sphenoidal sinusitis, unspecified
T39.1X5A Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.1X5S Adverse effect of 4-Aminophenol derivatives, sequela
T39.1X5D Adverse effect of 4-Aminophenol derivatives, subsequent encounter
T44.6X5A Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.6X5S Adverse effect of alpha-adrenoreceptor antagonists, sequela
T44.6X5D Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
T36.5X5A Adverse effect of aminoglycosides, initial encounter
T36.5X5S Adverse effect of aminoglycosides, sequela
T36.5X5D Adverse effect of aminoglycosides, subsequent encounter
T43.625A Adverse effect of amphetamines, initial encounter
T43.625S Adverse effect of amphetamines, sequela
T43.625D Adverse effect of amphetamines, subsequent encounter
T50.7X5A Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.7X5S Adverse effect of analeptics and opioid receptor antagonists, sequela
T50.7X5D Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter
T38.7X5A Adverse effect of androgens and anabolic congeners, initial encounter
T38.7X5S Adverse effect of androgens and anabolic congeners, sequela
T38.7X5D Adverse effect of androgens and anabolic congeners, subsequent encounter
T46.4X5A Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
T46.4X5S Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
T46.4X5D Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
T38.815A Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
T38.815S Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
T38.815D Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
T37.4X5A Adverse effect of anthelminthics, initial encounter
T37.4X5S Adverse effect of anthelminthics, sequela
T37.4X5D Adverse effect of anthelminthics, subsequent encounter
T45.0X5A Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5S Adverse effect of antiallergic and antiemetic drugs, sequela
T45.0X5D Adverse effect of antiallergic and antiemetic drugs, subsequent encounter
T48.6X5A Adverse effect of antiasthmatics, initial encounter
T48.6X5S Adverse effect of antiasthmatics, sequela
T48.6X5D Adverse effect of antiasthmatics, subsequent encounter
T44.0X5A Adverse effect of anticholinesterase agents, initial encounter
T44.0X5S Adverse effect of anticholinesterase agents, sequela
T44.0X5D Adverse effect of anticholinesterase agents, subsequent encounter
T45.7X5A Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
T45.7X5S Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
T45.7X5D Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
T45.515A Adverse effect of anticoagulants, initial encounter
T45.515S Adverse effect of anticoagulants, sequela
T45.515D Adverse effect of anticoagulants, subsequent encounter
T47.6X5A Adverse effect of antidiarrheal drugs, initial encounter
T47.6X5S Adverse effect of antidiarrheal drugs, sequela
T47.6X5D Adverse effect of antidiarrheal drugs, subsequent encounter
T50.6X5A Adverse effect of antidotes and chelating agents, initial encounter
T50.6X5S Adverse effect of antidotes and chelating agents, sequela
T50.6X5D Adverse effect of antidotes and chelating agents, subsequent encounter
T36.7X5A Adverse effect of antifungal antibiotics, systemically used, initial encounter
T36.7X5S Adverse effect of antifungal antibiotics, systemically used, sequela
T36.7X5D Adverse effect of antifungal antibiotics, systemically used, subsequent encounter
T38.6X5A Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
T38.6X5S Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
T38.6X5D Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
T46.6X5A Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T46.6X5S Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T46.6X5D Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
T37.2X5A Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
T37.2X5S Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
T37.2X5D Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter
T37.1X5A Adverse effect of antimycobacterial drugs, initial encounter
T37.1X5S Adverse effect of antimycobacterial drugs, sequela
T37.1X5D Adverse effect of antimycobacterial drugs, subsequent encounter
T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5S Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.1X5D Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T42.8X5A Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
42.8X5S Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
T42.8X5D Adverse effect of antiparkinsonism drugs and other central muscle-tonedepressants, subsequent encounter
T49.1X5A Adverse effect of antipruritics, initial encounter
T49.1X5S Adverse effect of antipruritics, sequela
T49.1X5D Adverse effect of antipruritics, subsequent encounter
T39.4X5A Adverse effect of antirheumatics, not elsewhere classified, initial encounter
T39.4X5S Adverse effect of antirheumatics, not elsewhere classified, sequela
T39.4X5D Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter
T45.525A Adverse effect of antithrombotic drugs, initial encounter
T45.525S Adverse effect of antithrombotic drugs, sequela
T45.525D Adverse effect of antithrombotic drugs, subsequent encounter
T38.2X5A Adverse effect of antithyroid drugs, initial encounter
T38.2X5S Adverse effect of antithyroid drugs, sequela
T38.2X5D Adverse effect of antithyroid drugs, subsequent encounter
T48.3X5A Adverse effect of antitussives, initial encounter
T48.3X5S Adverse effect of antitussives, sequela
T48.3X5D Adverse effect of antitussives, subsequent encounter
T46.8X5A Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
T46.8X5S Adverse effect of antivaricose drugs, including sclerosing agents, sequela
T46.8X5D Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
T37.5X5A Adverse effect of antiviral drugs, initial encounter
T37.5X5S Adverse effect of antiviral drugs, sequela
T37.5X5D Adverse effect of antiviral drugs, subsequent encounter
T50.5X5A Adverse effect of appetite depressants, initial encounter
T50.5X5S Adverse effect of appetite depressants, sequela
T50.5X5D Adverse effect of appetite depressants, subsequent encounter
T39.015A Adverse effect of aspirin, initial encounter
T39.015S Adverse effect of aspirin, sequela
T39.015D Adverse effect of aspirin, subsequent encounter
T42.3X5A Adverse effect of barbiturates, initial encounter
T42.3X5S Adverse effect of barbiturates, sequela
T42.3X5D Adverse effect of barbiturates, subsequent encounter
T42.4X5A Adverse effect of benzodiazepines, initial encounter
T42.4X5S Adverse effect of benzodiazepines, sequela
T42.4X5D Adverse effect of benzodiazepines, subsequent encounter
T44.7X5A Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5S Adverse effect of beta-adrenoreceptor antagonists, sequela
T44.7X5D Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
T43.4X5A Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.4X5S Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
T43.4X5D Adverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
T43.615A Adverse effect of caffeine, initial encounter
T43.615S Adverse effect of caffeine, sequela
T43.615D Adverse effect of caffeine, subsequent encounter
T46.1X5A Adverse effect of calcium-channel blockers, initial encounter
T46.1X5S Adverse effect of calcium-channel blockers, sequela
T46.1X5D Adverse effect of calcium-channel blockers, subsequent encounter
T40.7X5A Adverse effect of cannabis (derivatives), initial encounter
T40.7X5S Adverse effect of cannabis (derivatives), sequela
T40.7X5D Adverse effect of cannabis (derivatives), subsequent encounter
T50.2X5A Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
T50.2X5S Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and otherdiuretics, sequela
T50.2X5D Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter
T46.0X5A Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.0X5S Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
T46.0X5D Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T44.8X5A Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X5S Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.8X5D Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T36.1X5A Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
T36.1X5S Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
T36.1X5D Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
T36.2X5A Adverse effect of chloramphenicol group, initial encounter
T36.2X5S Adverse effect of chloramphenicol group, sequela
T36.2X5D Adverse effect of chloramphenicol group, subsequent encounter
T40.5X5A Adverse effect of cocaine, initial encounter
T40.5X5S Adverse effect of cocaine, sequela
T40.5X5D Adverse effect of cocaine, subsequent encounter
T46.3X5A Adverse effect of coronary vasodilators, initial encounter
T46.3X5S Adverse effect of coronary vasodilators, sequela
T46.3X5D Adverse effect of coronary vasodilators, subsequent encounter
T49.7X5A Adverse effect of dental drugs, topically applied, initial encounter
T49.7X5S Adverse effect of dental drugs, topically applied, sequela
T49.7X5D Adverse effect of dental drugs, topically applied, subsequent encounter
T50.8X5A Adverse effect of diagnostic agents, initial encounter
T50.8X5S Adverse effect of diagnostic agents, sequela
T50.8X5D Adverse effect of diagnostic agents, subsequent encounter
T47.5X5A Adverse effect of digestants, initial encounter
T47.5X5S Adverse effect of digestants, sequela
T47.5X5D Adverse effect of digestants, subsequent encounter
T50.4X5A Adverse effect of drugs affecting uric acid metabolism, initial encounter
T50.4X5S Adverse effect of drugs affecting uric acid metabolism, sequela
T50.4X5D Adverse effect of drugs affecting uric acid metabolism, subsequent encounter
T50.3X5A Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
T50.3X5S Adverse effect of electrolytic, caloric and water-balance agents, sequela
T50.3X5D Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter
T47.7X5A Adverse effect of emetics, initial encounter
T47.7X5S Adverse effect of emetics, sequela
T47.7X5D Adverse effect of emetics, subsequent encounter
T49.3X5A Adverse effect of emollients, demulcents and protectants, initial encounter
T49.3X5S Adverse effect of emollients, demulcents and protectants, sequela
T49.3X5D Adverse effect of emollients, demulcents and protectants, subsequent encounter
T45.3X5A Adverse effect of enzymes, initial encounter
T45.3X5S Adverse effect of enzymes, sequela
T45.3X5D Adverse effect of enzymes, subsequent encounter
T48.4X5A Adverse effect of expectorants, initial encounter
T48.4X5S Adverse effect of expectorants, sequela
T48.4X5D Adverse effect of expectorants, subsequent encounter

T44.2X5A Adverse effect of ganglionic blocking drugs, initial encounter
T44.2X5S Adverse effect of ganglionic blocking drugs, sequela
T44.2X5D Adverse effect of ganglionic blocking drugs, subsequent encounter
T38.0X5A Adverse effect of glucocorticoids and synthetic analogues, initial encounter
T38.0X5S Adverse effect of glucocorticoids and synthetic analogues, sequela
T38.0X5D Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter
T45.625A Adverse effect of hemostatic drug, initial encounter
T45.625S Adverse effect of hemostatic drug, sequela
T45.625D Adverse effect of hemostatic drug, subsequent encounter
T47.0X5A Adverse effect of histamine H2-receptor blockers, initial encounter
T47.0X5S Adverse effect of histamine H2-receptor blockers, sequela
T47.0X5D Adverse effect of histamine H2-receptor blockers, subsequent encounter
T42.0X5A Adverse effect of hydantoin derivatives, initial encounter
T42.0X5S Adverse effect of hydantoin derivatives, sequela
T42.0X5D Adverse effect of hydantoin derivatives, subsequent encounter
T42.1X5A Adverse effect of iminostilbenes, initial encounter
T42.1X5S Adverse effect of iminostilbenes, sequela
T42.1X5D Adverse effect of iminostilbenes, subsequent encounter
T50.Z15A Adverse effect of immunoglobulin, initial encounter
T50.Z15S Adverse effect of immunoglobulin, sequela
T50.Z15D Adverse effect of immunoglobulin, subsequent encounter
T41.0X5A Adverse effect of inhaled anesthetics, initial encounter
T41.0X5S Adverse effect of inhaled anesthetics, sequela
T41.0X5D Adverse effect of inhaled anesthetics, subsequent encounter
T38.3X5A Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
T38.3X5S Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
T38.3X5D Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
T41.1X5A Adverse effect of intravenous anesthetics, initial encounter
T41.1X5S Adverse effect of intravenous anesthetics, sequela
T41.1X5D Adverse effect of intravenous anesthetics, subsequent encounter
T45.4X5A Adverse effect of iron and its compounds, initial encounter
T45.4X5S Adverse effect of iron and its compounds, sequela
T45.4X5D Adverse effect of iron and its compounds, subsequent encounter
T49.4X5A Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
T49.4X5S Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
T49.4X5D Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, subsequent encounter
T41.3X5A Adverse effect of local anesthetics, initial encounter
T41.3X5S Adverse effect of local anesthetics, sequela
T41.3X5D Adverse effect of local anesthetics, subsequent encounter
T49.0X5A Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
T49.0X5S Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
T49.0X5D Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter
T49.2X5A Adverse effect of local astringents and local detergents, initial encounter
T49.2X5S Adverse effect of local astringents and local detergents, sequela
T49.2X5D Adverse effect of local astringents and local detergents, subsequent encounter
T50.1X5A Adverse effect of loop [high-ceiling] diuretics, initial encounter
T50.1X5S Adverse effect of loop [high-ceiling] diuretics, sequela
T50.1X5D Adverse effect of loop [high-ceiling] diuretics, subsequent encounter